INVO Fertility (NASDAQ:IVF) Announces Earnings Results

by · The Markets Daily

INVO Fertility (NASDAQ:IVF – Get Free Report) posted its earnings results on Friday. The company reported $0.35 earnings per share for the quarter, Zacks reports. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

INVO Fertility Price Performance

Shares of INVO Fertility stock traded up $0.00 during trading on Friday, hitting $0.97. 48,505 shares of the stock traded hands, compared to its average volume of 78,813. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. The stock has a market cap of $2.23 million, a price-to-earnings ratio of -0.00 and a beta of 2.32. The firm’s fifty day moving average is $1.27 and its 200-day moving average is $2.61. INVO Fertility has a 52 week low of $0.90 and a 52 week high of $84.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Check Out Our Latest Research Report on IVF

Institutional Trading of INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new position in shares of INVO Fertility, Inc (NASDAQ:IVF – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

(Get Free Report)

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.

Featured Stories